Table 2.
Activity of the synthesized peptides against cytomegalovirus (HCMV) in human embryonic lung (HEL) cells.
| Peptide | Antiviral Activity (EC50, µM) a | Cytotoxicity (µM) | ||
|---|---|---|---|---|
| AD-169 Strain | Davis Strain | Cell Morphology (MCC) b | Cell Growth (CC50) c | |
| AT1001 (1) | >20 | >20 | ≥100 | ND d |
| 2 | >20 | >20 | ≥20 | ND d |
| 3 | >20 | >100 | ≥20 | ND d |
| 4 | >20 | 100 | 100 | ND d |
| 5 | >20 | >100 | ≥100 | ND d |
| 6 | >4 | >20 | ≥20 | ND d |
| Ganciclovir | 2.56 ± 0.23 | 1.18 | ≥394 | 350.23 |
| Cidofovir | 1.27 ± 0.18 | 0.67 ± 0.49 | ≥317 | 159.22 ± 76.5 |
a Effective concentration required to reduce virus cytopathic effect by 50%. Virus input was 100 CCID50. b Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology. c Cytotoxic concentration required to reduce cell growth by 50%. d Not determined.